Monte Rosa Therapeutics (GLUE) Competitors $7.74 -0.74 (-8.73%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GLUE vs. CCCC, ICVX, KNTE, IVVD, MCRB, MIRM, RXRX, CNTA, WVE, and HRMYShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include C4 Therapeutics (CCCC), Icosavax (ICVX), Kinnate Biopharma (KNTE), Invivyd (IVVD), Seres Therapeutics (MCRB), Mirum Pharmaceuticals (MIRM), Recursion Pharmaceuticals (RXRX), Centessa Pharmaceuticals (CNTA), Wave Life Sciences (WVE), and Harmony Biosciences (HRMY). These companies are all part of the "medical" sector. Monte Rosa Therapeutics vs. C4 Therapeutics Icosavax Kinnate Biopharma Invivyd Seres Therapeutics Mirum Pharmaceuticals Recursion Pharmaceuticals Centessa Pharmaceuticals Wave Life Sciences Harmony Biosciences C4 Therapeutics (NASDAQ:CCCC) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation. Which has stronger valuation & earnings, CCCC or GLUE? C4 Therapeutics has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$33.67M9.04-$132.49M-$1.70-2.54Monte Rosa TherapeuticsN/AN/A-$135.35M-$1.83-4.23 Is CCCC or GLUE more profitable? Monte Rosa Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% Monte Rosa Therapeutics N/A -62.68%-38.83% Does the media prefer CCCC or GLUE? In the previous week, Monte Rosa Therapeutics had 6 more articles in the media than C4 Therapeutics. MarketBeat recorded 9 mentions for Monte Rosa Therapeutics and 3 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.44 beat Monte Rosa Therapeutics' score of 0.95 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, CCCC or GLUE? C4 Therapeutics has a beta of 3.04, meaning that its share price is 204% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Does the MarketBeat Community prefer CCCC or GLUE? C4 Therapeutics received 12 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. However, 48.28% of users gave Monte Rosa Therapeutics an outperform vote while only 38.81% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2638.81% Underperform Votes4161.19% Monte Rosa TherapeuticsOutperform Votes1448.28% Underperform Votes1551.72% Do analysts recommend CCCC or GLUE? C4 Therapeutics presently has a consensus price target of $11.20, indicating a potential upside of 159.86%. Monte Rosa Therapeutics has a consensus price target of $16.00, indicating a potential upside of 106.72%. Given C4 Therapeutics' higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Monte Rosa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in CCCC or GLUE? 78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 8.6% of C4 Therapeutics shares are held by insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryC4 Therapeutics beats Monte Rosa Therapeutics on 11 of the 17 factors compared between the two stocks. Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$475.52M$2.94B$5.12B$8.72BDividend YieldN/A1.81%5.18%4.07%P/E Ratio-4.2320.4872.8114.16Price / SalesN/A224.491,250.2081.71Price / CashN/A176.6640.7036.03Price / Book2.324.056.455.94Net Income-$135.35M-$42.42M$119.73M$225.73M7 Day Performance-16.41%-10.63%-5.13%-1.34%1 Month Performance40.98%-5.81%-2.71%1.15%1 Year Performance131.04%24.19%31.08%24.02% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics3.1595 of 5 stars$7.74-8.7%$16.00+106.7%+138.9%$475.52MN/A-4.2390Short Interest ↑CCCCC4 Therapeutics2.1482 of 5 stars$5.13-6.9%N/A+136.8%$362.13M$20.76M-3.02150Short Interest ↓ICVXIcosavaxN/A$15.31flatN/AN/A$766.88M$580,000.00-6.9060KNTEKinnate Biopharma1.3779 of 5 stars$2.65-0.4%N/A+17.3%$125.13MN/A-0.9584High Trading VolumeIVVDInvivyd2.6254 of 5 stars$0.89-11.0%N/A-49.7%$106.30MN/A-0.49100Short Interest ↑News CoverageGap UpHigh Trading VolumeMCRBSeres Therapeutics4.0807 of 5 stars$0.59-10.6%N/A-52.6%$100.45M$126.32M-0.50233Analyst ForecastNews CoverageGap UpMIRMMirum Pharmaceuticals4.2693 of 5 stars$43.92+3.9%N/A+46.8%$2.10B$186.37M-21.74140Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews CoverageRXRXRecursion Pharmaceuticals2.1201 of 5 stars$7.32-3.4%N/A-7.4%$2.06B$44.58M-4.78400Insider SellingCNTACentessa Pharmaceuticals3.8575 of 5 stars$18.08+6.4%N/A+129.2%$2.05B$6.85M-11.8272Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeWVEWave Life Sciences4.8719 of 5 stars$15.69-1.3%N/A+149.0%$1.96B$110.50M-14.14240Analyst ForecastInsider SellingShort Interest ↑Analyst RevisionNews CoverageHRMYHarmony Biosciences4.8494 of 5 stars$33.84-3.5%N/A+28.5%$1.93B$582.02M16.04200Short Interest ↓ Related Companies and Tools Related Companies CCCC Alternatives ICVX Alternatives KNTE Alternatives IVVD Alternatives MCRB Alternatives MIRM Alternatives RXRX Alternatives CNTA Alternatives WVE Alternatives HRMY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLUE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
